Short Interest in Organogenesis Holdings Inc. (NASDAQ:ORGO) Expands By 29.1%

Organogenesis Holdings Inc. (NASDAQ:ORGO) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 11,000,000 shares, a growth of 29.1% from the November 30th total of 8,520,000 shares. Approximately 16.3% of the shares of the stock are sold short. Based on an average daily volume of 690,900 shares, the days-to-cover ratio is presently 15.9 days.

Insider Buying and Selling

In related news, CEO Gary S. Gillheeney sold 157,448 shares of Organogenesis stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $3.64, for a total value of $573,110.72. Following the transaction, the chief executive officer now directly owns 3,143,753 shares of the company’s stock, valued at $11,443,260.92. This trade represents a 4.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold 278,116 shares of company stock valued at $991,190 over the last quarter. 36.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Organogenesis

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Captrust Financial Advisors bought a new stake in Organogenesis during the 3rd quarter worth $36,000. Delap Wealth Advisory LLC acquired a new stake in shares of Organogenesis during the second quarter valued at about $40,000. Intech Investment Management LLC bought a new stake in shares of Organogenesis during the third quarter worth about $43,000. Allspring Global Investments Holdings LLC increased its stake in shares of Organogenesis by 4,989.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock valued at $44,000 after buying an additional 15,369 shares during the period. Finally, Pallas Capital Advisors LLC increased its stake in shares of Organogenesis by 70.8% in the third quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock valued at $63,000 after buying an additional 9,048 shares during the period. 49.57% of the stock is owned by institutional investors.

Organogenesis Price Performance

Shares of ORGO stock traded up $0.04 during trading hours on Tuesday, reaching $3.20. The company’s stock had a trading volume of 522,404 shares, compared to its average volume of 833,463. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. Organogenesis has a fifty-two week low of $2.16 and a fifty-two week high of $4.70. The company has a market capitalization of $402.32 million, a price-to-earnings ratio of -53.33 and a beta of 1.73. The firm’s 50 day simple moving average is $3.46 and its 200-day simple moving average is $3.04.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to analyst estimates of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period last year, the firm posted $0.02 earnings per share. Sell-side analysts forecast that Organogenesis will post -0.07 earnings per share for the current year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.